The groundbreaking success of Viagra undeniably transformed the drug landscape, but placing funds in companies strongly reliant on unbranded versions presents a complex picture. While early returns were substantial, the cessation of patents and the emergence of less expensive alternatives have weakened the customer base. Consequently, a thorough an